During pregnancy, use of the antiepileptic drug valproic acid has been associated with worse outcomes—including fetal loss, impaired growth, major congenital malformations, increased risk of developmental problems, and autism—compared with all other antiepileptic drugs.
During pregnancy, use of the antiepileptic drug valproic acid has been associated with worse outcomes—including fetal loss, impaired growth, major congenital malformations, increased risk of developmental problems, and autism—compared with all other antiepileptic drugs. A new Epilepsia study has found that when human placentas are exposed to valproic acid, they express lower levels of transporters for compounds essential for fetal growth and development (such as glucose and folic acid).
The findings suggest that valproic acid’s effects on the placenta may be involved in the adverse developmental outcomes seen in fetuses exposed to the drug.
"Despite the risk, there are cases in which valproic acid may be the only drug that can control seizures in pregnant women,” said senior author Dr. Sara Eyal, of the Hebrew University of Jerusalem, in Israel. “We continue our studies to understand why some fetuses are adversely affected by valproic acid whereas others are not.”
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/epi.14078
About Journal
Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, Epilepsia presents subscribers with scientific evidence and clinical methodology in clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology and therapeutic trials.
Each monthly issue features original peer reviewed articles, brief communications, editorial commentaries, meeting reports, and announcements.
Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com